Sanofi licenses 5 drugs to Covis

04/8/2013 | Pharmaceutical Business Review Online · Drug Store News

Switzerland's Covis Pharma agreed to acquire the U.S. commercial rights to five drugs from Sanofi-Aventis and its units. The deal covers the prostate cancer drug Nilandron; Plaquenil, a drug for malaria, lupus and arthritis; amyotrophic lateral sclerosis drug Rilutek; Uroxatral, a drug for enlarged prostate; and high-potassium treatment Kayexalate. Sanofi keeps the products' rights elsewhere in the world.

View Full Article in:

Pharmaceutical Business Review Online · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX